Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon alpha + ribavirin
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Pegylated interferon alpha + ribavirin is a combination antiviral therapy used primarily for the treatment of chronic hepatitis C virus (HCV) infection. The regimen consists of a pegylated form of interferon alpha (either alfa-2a or alfa-2b), which is a cytokine that exerts its effects by binding to cell surface receptors and inducing antiviral, antiproliferative, and immunomodulatory activities. Pegylation increases the half-life of interferon alpha, allowing for once-weekly dosing. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity; it inhibits viral RNA synthesis and viral mRNA capping. Together, these agents act synergistically to enhance sustained virologic response rates in HCV-infected patients compared to monotherapy. This combination was considered standard-of-care before the advent of direct-acting antivirals[1][3][5].
- Brand names
- Pegasys + CopegusPEG-Intron + Rebetol
- Other names
- peginterferon alfa-2a + ribavirinpeginterferon alfa-2b + ribavirinPEG-IFNα/RBV
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on pegylated interferon alpha + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon alpha + ribavirin.